» Articles » PMID: 21753898

Twelve Cases of Drug-induced Blepharospasm Improved Within 2 Months of Psychotropic Cessation

Overview
Publisher Dove Medical Press
Specialty Health Services
Date 2011 Jul 15
PMID 21753898
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To determine whether psychotropic cessation in patients with drug-induced blepharospasm improves motor symptoms.

Methods: In patients with drug-induced blepharospasm, we withdrew part or all of their psychotropic medication and assessed motor symptoms using the Jankovic rating scale (0 = none, 1 = noticeable, 2 = mild, 3 = moderate, 4 = severe) at first presentation and after cessation.

Results: Twelve patients (eleven women and one man, mean age 60.4 years) were enrolled. Psychotropics were administered before the onset of blepharospasm in all patients. The mean duration of treatment with psychotropic medication was 47.3 (range 3-120) months. Jankovic rating scale at initial presentation was 3 in eleven patients and 2 in one patient. After cessation, blepharospasm started to improve in all cases within 2 months (average 3.9 weeks). While the effect of psychotropic cessation was variable, the symptoms eventually improved to more than 2 on the rating scale. Three of the twelve patients underwent a single botulinum neurotoxin injection and were withdrawn from therapy after cessation.

Conclusion: Psychotropic drugs can cause blepharospasm in some cases. Clinicians should consider reducing psychotropic medication as far as possible in patients with blepharospasm taking these agents.

Citing Articles

Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system.

Toyoshima M, Noguchi Y, Otsubo M, Tachi T, Teramachi H Int J Med Sci. 2021; 18(5):1130-1136.

PMID: 33526972 PMC: 7847624. DOI: 10.7150/ijms.51658.


Association of Systemic Comorbidities with Dry Eye Disease.

Kawashima M, Yamada M, Shigeyasu C, Suwaki K, Uchino M, Hiratsuka Y J Clin Med. 2020; 9(7).

PMID: 32610609 PMC: 7408955. DOI: 10.3390/jcm9072040.


Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo.

Wakakura M, Yamagami A, Iwasa M Neuroophthalmology. 2018; 42(5):275-283.

PMID: 30258472 PMC: 6152494. DOI: 10.1080/01658107.2017.1409770.


Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database.

Noguchi Y, Ueno A, Katsuno H, Otsubo M, Yoshida A, Kanematsu Y J Pharm Health Care Sci. 2018; 4:10.

PMID: 29760940 PMC: 5937044. DOI: 10.1186/s40780-018-0106-2.


Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis.

Martinez-Ramirez D, Giugni J, Hastings E, Wagle Shukla A, Malaty I, Okun M Tremor Other Hyperkinet Mov (N Y). 2015; 4:286.

PMID: 25562037 PMC: 4266684. DOI: 10.7916/D8H41Q4X.

References
1.
Wakakura M, Tsubouchi T, Inouye J . Etizolam and benzodiazepine induced blepharospasm. J Neurol Neurosurg Psychiatry. 2004; 75(3):506-7. PMC: 1738986. DOI: 10.1136/jnnp.2003.019869. View

2.
Soares-Weiser K, Rathbone J . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1):CD000459. DOI: 10.1002/14651858.CD000459.pub2. View

3.
Jankovic J, Orman J . Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987; 37(4):616-23. DOI: 10.1212/wnl.37.4.616. View

4.
Mauriello Jr J, Carbonaro P, Dhillon S, Leone T, Franklin M . Drug-associated facial dyskinesias--a study of 238 patients. J Neuroophthalmol. 1998; 18(2):153-7. View

5.
Hallett M, Evinger C, Jankovic J, Stacy M . Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008; 71(16):1275-82. PMC: 2676990. DOI: 10.1212/01.wnl.0000327601.46315.85. View